On June 8, the Kearney Hub published an article by Christopher Rowland of the Washington Post that addressed the decision by Pfizer and Amgen not to pursue the drug Enbrel for Alzheimer’s disease and not to publish the data they had from preliminary investigations.
Alzheimer’s is a personally devastating and fatal disease. According to the Alzheimer’s Association 2019 Facts and Figures report, Alzheimer’s is the sixth leading cause of death in the United States and in Nebraska, with the number of people affected by the disease increasing daily.
As executive director of the Alzheimer’s Association Nebraska Chapter, I want Nebraska residents to know that it is the expectation of our organization and our constituents that every possible treatment or prevention path is pursued thoroughly and aggressively — with people living with Alzheimer’s and other dementias as a priority. No stone should be left unturned in the pursuit of treatments, preventions and a cure for Alzheimer’s disease and other dementias.
Any science that has promise for Alzheimer’s disease and other dementias and is not pursued genuinely or shared with the research community does a disservice to not only our Nebraska families affected by this disease, but the millions of families affected around of the world.
The Alzheimer’s Association believes strongly in sharing data for the benefit of the entire research field and ultimately for the benefit of people with Alzheimer’s disease, and will continue to do so. Please consider getting involved in Alzheimer’s research in some capacity, and learn more about how to do so at alz.org.
Sharon Stephens, Kearney